ADC Analysis via IdeS Digestion and LC-MS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for characterizing and quantifying antibody-drug conjugates (ADCs) face challenges due to their heterogeneous composition and complex structural modifications, leading to inconsistent measurement of pharmacokinetic parameters and in vivo performance, especially with next-generation ADCs that have new types of linkers and payloads.
Innovation Solution
The affinity capture LC-MS F(ab′)2 assay is used, which involves binding ADCs to the Fab region, followed by IdeS digestion to remove the Fc domain, resulting in F(ab′)2 fragments that are more amenable to electrospray ionization LC-MS analysis, improving sensitivity and resolution, and reducing assay artifacts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If affinity capture LC-MS is used for intact ADC analysis, then drug-to-antibody ratio characterization is achieved, but sensitivity and resolution are insufficient for complex next-generation ADCs
Solution Approach 1:
The patent applies segmentation by digesting the intact ADC into smaller peptide fragments using proteolytic enzymes. This breaks down the complex intact ADC structure into manageable pieces that can be analyzed with higher sensitivity and resolution by LC-MS, directly resolving the contradiction between measurement precision and device/structure complexity.
Solution Approach 2:
The patent extracts specific peptide fragments containing the drug-antibody linkage information from the intact ADC through enzymatic digestion. By isolating and analyzing only the relevant peptide fragments rather than the entire intact ADC, the method achieves higher measurement precision for DAR characterization while managing the complexity of next-generation ADC structures.
2Measurement precision
If intact ADC affinity capture LC-MS assay is used, then DAR characterization is achieved, but assay artifacts occur due to prolonged incubation times
Solution Approach 1:
The patent performs preliminary enzymatic digestion of the ADC into peptide fragments before LC-MS analysis. This preliminary action eliminates the need for prolonged incubation during the assay, preventing drug metabolism artifacts while maintaining accurate DAR characterization. The digestion is performed under controlled conditions prior to the actual measurement process.
3Quantity of substance
If current characterization methods are used for heterogeneous ADC compositions, then basic ADC properties are measured, but inconsistent pharmacokinetic parameters result
Solution Approach 1:
The patent applies local quality by focusing analysis on specific peptide fragments that contain drug-antibody linkage information rather than attempting to analyze the entire heterogeneous ADC population. This localized approach to analyzing specific regions of the ADC provides more consistent and precise pharmacokinetic parameters by avoiding the variability inherent in heterogeneous ADC compositions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides more detailed and accurate information on ADC biotransformations, enabling the analysis of low-dose, labile, and complex site-specific ADCs, with improved sensitivity and resolution, and minimizes biased responses to certain drug-to-antibody ratio species.
Implementation Method 1
followed by IdeS digestion to remove the Fc domain
Implementation Method 2
electrospray ionization LC-MS analysis
Implementation Method 3
Liquid chromatography-tandem mass spectrometry (LC-MS/MS)
Data Source
AI summary
Methods to rapidly and accurately detect, characterize, measure, and quantify site-specific antibody drug conjugates, that may be present in pre-clinical animal biological samples, or human biological samples, including plasma/serum and tissue samples.